Jonathan Chung to Seminoma
This is a "connection" page, showing publications Jonathan Chung has written about Seminoma.
Connection Strength
0.160
-
An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis. Eur Urol. 2019 01; 75(1):201-203.
Score: 0.160